Ankur Varma

Associate Professor

UAMS

Also affiliated: Rush University Medical Center (2019–2023); The University of Texas MD Anderson Cancer Center (2012–2020); Baylor College of Medicine (2016–2018); University of Arkansas Medical Center (2024); Coleman Foundation (2020); Rush University (2019–2023); The University of Texas Health Science Center at Houston (2014–2015)

COM | Internal Med Hem-Onc

13 h-index 83 pubs 859 cited

Research Areas

Biomedical Subjects

Links

ORCID Research Group UAMS TRI Profile

OverviewAI-generated summary

Ankur Varma studies hematopoietic stem cell transplantation (HSCT), focusing on immune reconstitution and treatment outcomes in patients with hematologic malignancies. His research investigates factors influencing recovery after HSCT, including the impact of specific conditioning regimens and the role of donor-specific anti-HLA antibodies. Varma has also explored prognostic assessment tools for patients with metastatic breast cancer and the prevalence of chronic kidney disease in specific populations.

His work includes examining markers that predict complications such as fluid overload in HSCT recipients. Varma has also investigated the effects of COVID-19 infection on hematopoietic cell transplant patients, considering variables like age and steroid use. He has published 94 papers, with an h-index of 14 and 975 citations. Key collaborators at the University of Arkansas for Medical Sciences include Mamatha Gaddam, César Sánchez, and Nishanth Thalambedu.

Metrics

h-index: 13
Publications: 83
Citations: 859

Positions

Associate Professor publications 2023–2026

University of Arkansas for Medical Sciences COM | Internal Med Hem-Onc Institutional directory

Selected Publications

CLL-888: Efficacy and Safety of CAR-T Therapy in Relapsed/Refractory Chronic Lymphocytic Leukemia: A Systematic Review and Meta-Analysis (2026)

Clinical Lymphoma Myeloma & Leukemia DOI OpenAlex
POSTER: CLL-1382: Comparing Ibrutinib With Acalabrutinib and Zanubrutinib in B-Cell Malignancies: A Real-World Study of Mortality and Toxicity (2026)

Clinical Lymphoma Myeloma & Leukemia DOI OpenAlex
POSTER: CLL-888: Efficacy and Safety of CAR-T Therapy in Relapsed/Refractory Chronic Lymphocytic Leukemia: A Systematic Review and Meta-Analysis (2026)

Clinical Lymphoma Myeloma & Leukemia DOI OpenAlex
CLL-1382: Comparing Ibrutinib With Acalabrutinib and Zanubrutinib in B-Cell Malignancies: A Real-World Study of Mortality and Toxicity (2026)

Clinical Lymphoma Myeloma & Leukemia DOI OpenAlex
In vivo CAR T-cell engineering in B-cell malignancies: A systematic review of emerging clinical and translational evidence. (2026)

Journal of Clinical Oncology DOI OpenAlex
Social vulnerability index as an independent poor prognostic factor in patients with chronic hematological malignancies in Arkansas. (2026)

Journal of Clinical Oncology DOI OpenAlex
Nonmyeloablative conditioning combined with the anti-CD117 antibody briquilimab in older adults with high-risk AML and MDS (2026)

Blood 5 citations DOI OpenAlex
Real-World Survival Outcomes of CAR-T and Bispecific T-cell Engagers in Patients with relapsed/refractory DLBCL (2026)

Transplantation and Cellular Therapy DOI OpenAlex
Impact of the CAR-T era on survival in diffuse large B-cell lymphoma: A u.S. population-based cohort study (2025)

Blood DOI OpenAlex
Can the development of drug-induced rash after mogamulizumab administration predict survival in mycosis fungoides/sezary syndrome? a trinetx-based analysis (2025)

Blood DOI OpenAlex
Revaccination status after bone marrow transplant and chimeric antigen receptor T-cell therapy. (2025)

JCO Oncology Practice DOI OpenAlex
Navigating Hyperhemolysis in Sickle Cell Disease: Insights from Literature (2025)

Diagnostics 8 citations DOI OpenAlex
The Effect of Sickle Cell Disease on Seizure-Related Hospitalizations: An Analysis of the Nationwide Inpatient Sample 2021 (2025)

Cureus DOI OpenAlex
Epidemiological and clinical trends in common hematological malignancies in Arkansas: Arkansas Central Cancer Registry (ACCR)-based study. (2025)

Journal of Clinical Oncology DOI OpenAlex
Unveiling Myelodysplastic Syndromes: Exploring Pathogenic Mechanisms and Therapeutic Advances (2025)

Cancers 5 citations DOI OpenAlex

View all publications on OpenAlex →

Grants & Funding

As listed on this researcher's institutional profile.

MYELOMATCH, Master Screening and Reassessment Protocol (MSRP) for Tier Advancement in the NCI myeloMATCH Clinical Trials NIH/Nat. Cancer Institute via SouthWest Oncology Group Principal Investigator